You are herePharma News
Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
(20th June, 2014); Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in adults with Type 2 Diabetes (T2D) at the American Diabetes Association's 74th Scientific Sessions®. Results showed that empagliflozin in combination with certain other diabetes therapies reduced blood glucose, body weight and blood pressure.
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
(Business Wire India; 20th June, 2014); Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa® in patients with AF who undergo ablation. Results of the study are expected in 2016.
Wincere Inc. – Presents Emerging Trends in Precision Medicine; Enabling Implementation through Big Data and BioMarker Research
(Business Wire India; 19th June, 2014); Wincere Inc., a visionary full service contract research organization and life sciences focused consulting company today organized a panel discussion in association with International CMEs Oncology on “Precision Medicine – Trends in Oncology”, promising to revolutionize cancer research.
New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia
(Business Wire India; 16th June, 2014); Acute myeloid leukaemia (AML) is a devastating form of blood cancer that mainly affects people over 60 years old. For older patients who receive chemotherapy, the median survival is less than a year. Even though AML is considered rare, it accounts for around 18,860 new cases and 10,000 deaths in the US each year and is the most frequent cause of leukaemia-related deaths.
(Business Wire India; 5th June, 2014); A new report by the Advanced Medical Technology Association (AdvaMed) demonstrates the lack of awareness among consumers about medical devices.
The findings of a survey of 1300 Indians from across 17 states conducted by AdvaMed – an association of medical device manufacturers leading the effort to provide medical technology to the world – reveals that although an overwhelming 72% of respondents use medical devices, 89% say that they do not know enough about them.
New study reported Prevena™ therapy patients had a significantly Lower Infection Rate following Cardiac Surgery compared to control group
(Business Wire India; 5th June, 2014); Kinetic Concepts, Inc. announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incisions for the first six to seven days reported a significantly lower infection rate than conventional dressings in patients undergoing cardiac surgery via median sternotomy. Post-sternotomy wound infection is a serious, potentially fatal complication of cardiac surgery which often requires additional surgery, and is associated with significantly increased health care costs.
(Business Wire India; 3rd June, 2014); Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.
(1st June, 2014); Dr Harsh Vardhan, Union Minister for Health and Family Welfare, has asked for thorough streamlining of systems in the distribution of free generic drugs to government health institutions at all levels throughout the country. The Free Drug Programme’s formal launch would be preceded by working out all logistical details with respect to procurement and distribution in consultation with the state governments.
(Business Wire India; 28th May, 2014); Colgate-Palmolive (India) Limited, the market leader in Oral Care, launched a toothpaste with first of its kind technology – Colgate Maximum Cavity Protection Plus Sugar Acid Neutralizer TM.
(22nd May, 2014);The U.S. Food and Drug Administration (FDA) approved the Immucor PreciseType Human Erythrocyte Antigen (HEA) Molecular BeadChip Test (BeadChip Test), manufactured by BioArray Solutions Ltd. of Warren, New Jersey, the first FDA-approved molecular assay used in transfusion medicine to assist in determining blood compatibility. The assay can be used to determine donor and patient non-ABO/non-RhD (non-ABO) red blood cell (RBC) types in the United States.